Navigation Links
Genaera Corporation Announces First Quarter Financial Results
Date:5/9/2008

PLYMOUTH MEETING, Pa., May 9 /PRNewswire-FirstCall/ -- Genaera Corporation (Nasdaq: GENR) today announced its financial results for the quarter ended March 31, 2008. The net loss for the quarter ended March 31, 2008 was $4.3 million, or $(0.24) per basic and diluted share, as compared to a net loss of $4.2 million, or $(0.24) per basic and diluted share, for the quarter ended March 31, 2007.

Genaera's research and development expenses for the quarter ended March 31, 2008 were $3.8 million compared to $3.5 million for the same period in 2007. The increase was due to increases in expenses related to the trodusquemine (MSI-1436) program for obesity and type 2 diabetes and a net increase in indirect expenses due to an increase in stock-based compensation related to stock options granted, partially offset by decreases in realignment costs and other indirect costs. These increases were partially offset by decreases in expenses related to the squalamine program for the treatment of wet age-related macular degeneration, the LOMUCIN(TM) program for the treatment of cystic fibrosis and the anti-IL9 antibody program.

Genaera's general and administrative expenses for the quarter ended March 31, 2008 were $2.2 million compared to $1.4 million for the same period in 2007. The increase was due to increases in stock-based compensation expense and an increase in legal fees.

The Company's cash, cash equivalents and short-term investments balance was $17.1 million at March 31, 2008.

About Genaera

Genaera Corporation is focused on advancing the science and treatment of metabolic diseases. The Company has significant market opportunities with a first-in-class molecule, trodusquemine (MSI-1436), that has the potential to rede
'/>"/>

SOURCE Genaera Corporation
Copyright©2008 PR Newswire.
All rights reserved

0

GOOD

Page: 1 2 3 4

Related biology technology :

1. Genaera Corporation Announces 2007 Financial Results
2. Genaera Corporation to Participate in Diabetes and Obesity Panel at RBC Capital Markets Healthcare Conference
3. Genaera Corporation Announces Third Quarter Financial Results
4. Genaera to Present at Biotech 2007 and BIO InvestorForum
5. Genaera Elects New Board Member and Announces Executive Appointments
6. EUSA Pharma Completes Acquisition Of Cytogen Corporation
7. Pharmos Corporation Reports 2008 First Quarter Results
8. Alsius Corporation to Host First Quarter 2008 Financial Results Conference Call on May 15, 2008
9. Mac-Gray Corporation Announces First-Quarter 2008 Financial Results
10. MannKind Corporation Reports First Quarter Financial Results
11. Eisai Corporation of North America Announces Appointment of Cynthia Schwalm as President, Eisai Inc.
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:12/4/2009)Alberta Centre for Advanced Micro Nano Technology Products (ACAMP) hosts, health & medical seminar, , EDMONTON, Dec. 4 /PRNewswire/ - Today ACAMP hosted a health & medical seminar, explaini
(Date:12/3/2009)DALLAS, Dec. 3 ACCESS PHARMACEUTICALS, INC. (OTC Bulletin Board: ACCP), today provided an update on its European commercial launch of MuGard, an FDA approved treatment for oral mucositis, a deb
(Date:12/3/2009)HOPKINTON, Mass., Dec. 3 Caliper Life Sciences, Inc. (Nasdaq: CALP ), a leading provider of tools and services for drug discovery and life sciences research, today introduced Living Image 4.0 softwa
(Date:12/2/2009)NEW YORK, Dec. 2 Reportlinker.com announces that a new market research report is available in its catalogue: ,, Carbondioxide Incubators - A Global Market Perspective ,, http://www.reportlinker.co
Breaking Biology Technology:Alberta companies delivering new products to the health & medical marketplace 2Access Pharmaceuticals Provides Update on MuGard Commercial Launch in Europe 2Access Pharmaceuticals Provides Update on MuGard Commercial Launch in Europe 3Access Pharmaceuticals Provides Update on MuGard Commercial Launch in Europe 4Caliper Life Sciences Launches Living Image(R) 4.0 Software 2Reportlinker Adds Carbondioxide Incubators - A Global Market Perspective 2Reportlinker Adds Carbondioxide Incubators - A Global Market Perspective 3Reportlinker Adds Carbondioxide Incubators - A Global Market Perspective 4
... to Host Investor Conference Call on Monday, May 1... EDT, NEW YORK, May 9 Keryx Biopharmaceuticals,I...focused on the,acquisition, development and commer...tical products for the treatment of life-threateni...oday announced its results,for the first quarter e...
...ND, Calif., May 9 (Nasdaq: WHRT, TSX:,WHT) Since ...y") has,aggressively pursued various financing alt...hrough equity financing transactions and corporate...At April 30, 2008, the,Company had cash and cash e...nt liabilities of approximately $2.6 million. On M...
..., Fla., May 9 The Cancer Research Alliance, an,or...ncer centers including,Moffitt Cancer Center, is a...power over cancer by stepping up and donating $1 t...h Father,s Day., The campaign, dubbed the "Infini...o activate Americans everywhere to take matters in...
Other Biology Technology:Keryx Biopharmaceuticals, Inc. Announces First Quarter 2008 Financial Results 2Keryx Biopharmaceuticals, Inc. Announces First Quarter 2008 Financial Results 3Keryx Biopharmaceuticals, Inc. Announces First Quarter 2008 Financial Results 4Keryx Biopharmaceuticals, Inc. Announces First Quarter 2008 Financial Results 5WorldHeart Reports an Event of Default Under the Note Issued to Abiomed, Resignation of One of Its Board of Directors, and Results of Shareholder Vote at Its Annual Shareholders' Meeting 2WorldHeart Reports an Event of Default Under the Note Issued to Abiomed, Resignation of One of Its Board of Directors, and Results of Shareholder Vote at Its Annual Shareholders' Meeting 3WorldHeart Reports an Event of Default Under the Note Issued to Abiomed, Resignation of One of Its Board of Directors, and Results of Shareholder Vote at Its Annual Shareholders' Meeting 4Moffitt Cancer Center Joins National Campaign To Implore Americans To Donate $1 To Accelerate Cancer Research 2
(Date:12/3/2009)Contents of this message: , , Preliminary Press Conference Topics, Last Call! Press Field Trip to California Academy of Sciences museum, Attention PIOs: Sending Press Releases to Fall meeting, N
(Date:12/3/2009)Grand Rapids, Mich. (Dec. 3, 2009) Van Andel Research Institute (VARI) researchers have determined precisely how the plant hormone abscisic acid (ABA) works at the molecular level to help plants re
(Date:12/3/2009)Forest dwellers must be included in the design of the upcoming forest deal at Copenhagen in order to avoid a humanitarian crisis, according to a scientist at the University of Leeds. , Writing today
Breaking Biology News(10 mins):AGU fall meeting: Preliminary press conference topics, press pre-registration deadline 2AGU fall meeting: Preliminary press conference topics, press pre-registration deadline 3AGU fall meeting: Preliminary press conference topics, press pre-registration deadline 4AGU fall meeting: Preliminary press conference topics, press pre-registration deadline 5AGU fall meeting: Preliminary press conference topics, press pre-registration deadline 6VAI researchers find long awaited key to creating drought resistant crops 2VAI researchers find long awaited key to creating drought resistant crops 3Forest deal at Copenhagen must avoid creating 'carbon refugees' 2Patient Centered Primary Care Collaborative Stakeholders Come to Washington DC for July Working Meeting 49072 1Patient Centered Primary Care Collaborative Stakeholders Come to Washington DC for July Working Meeting 49072 2Patient Centered Primary Care Collaborative Stakeholders Come to Washington DC for July Working Meeting 49072 3Data Presented at Society of Nuclear Medicine 2009 Annual Meeting Supports Potential of Peregrines Cotara 28R 29 for the Treatment of Brain Cancer 12651 1Data Presented at Society of Nuclear Medicine 2009 Annual Meeting Supports Potential of Peregrines Cotara 28R 29 for the Treatment of Brain Cancer 12651 2Data Presented at Society of Nuclear Medicine 2009 Annual Meeting Supports Potential of Peregrines Cotara 28R 29 for the Treatment of Brain Cancer 12651 3Data Presented at Society of Nuclear Medicine 2009 Annual Meeting Supports Potential of Peregrines Cotara 28R 29 for the Treatment of Brain Cancer 12651 4Data Presented at Society of Nuclear Medicine 2009 Annual Meeting Supports Potential of Peregrines Cotara 28R 29 for the Treatment of Brain Cancer 12651 5Data Presented at Society of Nuclear Medicine 2009 Annual Meeting Supports Potential of Peregrines Cotara 28R 29 for the Treatment of Brain Cancer 12651 6Government of Canada supports research to help address medical isotope shortage 49067 1
...ne is an ongoing challenge to blood services world...akob Disease (vCJD), emerge. An update on the late...orm of Bovine Spongiform Encephalopathy (BSE), com... transmission through blood transfusion was presen...nsfusion Congress. At the "Safety in Transfusion M...
...rs have learned how a common fish found along the ...same time. , The study marks the first time that s...n between the part of a vertebrate,s brain that co... ear that hears sound. The researchers believe tha...n midshipman fish (Porichthys notatus ) -- a 6- to...
...ing chemicals called neurotransmitters. One of tho...mma amino butyric acid), shows up in unusually hig...a new study from Washington University School of M...ed metastatic neuroendocrine tumors, which include...ancers that spread to other parts of the body. The...
Other Biology News:New results validating Pall prion reduction filter disclosed at ISBT Congress 2New results validating Pall prion reduction filter disclosed at ISBT Congress 3How fish hear and make sounds at same time 2Neurotransmitters signal aggressive cancer, offer potential for early diagnosis 2Neurotransmitters signal aggressive cancer, offer potential for early diagnosis 3
...ccessories necessary for casting gels for mutation...phism analysis (SSCP) with the DCode universal mut... finger adaptor for use with an external chiller (....75 mm spacers, two 20-well 0.75 mm combs, and san...
...etry accessible to anyone in the lab. Novice and e...o Guavas on-demand cytometry systemsthe Guava Easy...ery compact for higher throughput, multi-color det...ute cell counts, 6 parameters (4 fluorescent color...
...ity of the BDTM LSR, the first UV benchtop analyze... BD LSR II has performance, capabilities, and flex... Free up your high-performance cell sorter by movi...the BD LSR II. The BD LSR II can be configured wit...
BD FACSArray bioanalyzer from BD Biosciences - Immunocytometry Systems
Biology Products: